6[6]Markert JM, Parker JN, Gillespie GY, et al. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes, 2001, 8:17-22.
7[7]Samoto K, Ehtesham M, Perng GC, et al. A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery, 2002, 50:599-605.
8[8]Nanda D, Vogels R, Havenga M, et al. Treatment of malignantgliomas with a replicating adenoviral vector expressing herpes sim plex virus-thymidine kinase. Cancer Res, 2001, 61:8743-8750.
9[9]Zhang Y, Jeong Lee H, Boado RJ, et al. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med, 2002, 4:183-194.
10[10]Miller CR, Williams CR, Buchsbaum DJ, et al. Intratumoral 5-fluo rouracil produced by cytosine deaminase/5-fluorocytosine gene ther apy is effective for experimental human glioblastomas. Cancer Res, 2002, 62:773-780.
二级参考文献45
1[1]Kleihus P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors[J]. Toxicol Pathol,2000 ;28:164-170
2[2]Hill JR, Kuriyama N, Kuriyama H, et al. Molecular neuropathology of astrocytic brain tumors[ J]. J Neurooncol, 1999 ;56:439-441
3[3]Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma,occurrence, significance and prognostic implications [ J ]. Front Biosci,2000;5:d213-231
4[4]Ng HK, Lam PYP. The molecular genetics of central nervous system tumors [ J ]. Pathology, 1998; 30( 2 ): 196-202
5[5]Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors.Advances in knowledge and treatment[ J]. CA Cancer Clin, 1998;48:331-360
6[6]Rasheed BK, Wiltshiro RN, Bigner SH, et al. Molecular pathogenesis of malignant gliomas[ J]. Curr Opin Oncol, 1999; 11:162-167
7[7]Groussia AC, Agnosti NJ, Rao JS, et al. Cytogenetic and molecular abnormalities in astrocytic gliomas[ J]. Oncol Rep. 2000; 7: 401-412
8[8]Reis RM, Konv-Lebleblicioglu D, Lopes JM, et al. Genetic profile of gliosarcomas[ J]. Am J Pathol,2000; 156:425-432
9[9]Kopnin BP. Targets of oncogenes and tumor suppressors: Key for understanding basic mechanisms of carcinogenesis [ J ]. Biochemistry, 2000;65: 2-27
10[10]Von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive alleotype and genetic analysis of 466 human nervous system tumors[ J]. J Neuropathol Exp Neurol,2000;59(6) :544-558
4Roberge D.Stereotactic radiosurgery in the management of intracranial gliomas[J].Technol Cancer Res Treat,2003,2(2):117-126.
5Nwokedi EC. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme[J].Neurosurgery,2002,50(1):41-47.
6Fazeny-Dorner. Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center[J]. Wien Klin Wochenschr,2003,115(11):389-397.
7Goetz. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times[J].J Neurooncol,2003,62(3):321-328.
8Johannesen TB.Intracavity fractionated balloon brachytherapy in glioblastoma[J]. Acta Neurochir (Wien),1999,141(2):127-133.
9Silvani A.Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma[J].Neurol Sci,2002,23(5):219-224.
10Kochii.Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma[J].J Neurooncol,2000,49(1):63-70.
